Status:
COMPLETED
Molecular Characterization and Outcomes of Aggressive B-Cell Lymphomas.
Lead Sponsor:
Andrés José Maria Ferreri
Conditions:
Diffuse Large B Cell Lymphoma (DLBCL)
Eligibility:
All Genders
18+ years
Brief Summary
This is a retrospective analysis of the presence of chromosomal rearrangements involving MYC, BCL2 and BCL6 genes by FISH in a retrospective, single-center series of large B-cell lymphomas, in order t...
Eligibility Criteria
Inclusion
- Histologically-confirmed diagnosis of LBCL (i.e., DLBCL, HGBCL, unclassifiable B-cell lymphoma with features intermediate between DLBCL and BL), or aggressive B-cell lymphomas with blastoid morphology (excluding blastoid variant of mantle cell lymphoma and lymphoblastic lymphoma)
- Histopathological diagnosis performed between 2000 and 2019.
- HIV sero-negativity
- Age ≥18
- Treatment with R-CHOP or other intensified polychemotherapy regimen
- Availability of adequate histopathological samples at diagnosis for FISH analysis
- Availability of clinical records and outcomes data
- Exclusion criteria
- • Histologic diagnosis other than DLBCL or unclassifiable B-cell lymphoma with features intermediate between DLBCL and BL
Exclusion
Key Trial Info
Start Date :
July 12 2022
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
July 12 2023
Estimated Enrollment :
555 Patients enrolled
Trial Details
Trial ID
NCT07181785
Start Date
July 12 2022
End Date
July 12 2023
Last Update
September 18 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
IRCCS San Raffaele Hospital
Milan, Italy